文献速递血栓与止血

Khorana评分与接受免疫检查点抑制剂治疗的癌症患者静脉和动脉血栓形成:一项丹麦队列研究

The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study.
PubMed 文献 · J Thromb Haemost · 2022-10-07

该丹麦队列研究纳入3946例启动免疫检查点抑制剂治疗且无其他抗凝指征的癌症患者,评估Khorana评分对6个月静脉和动脉血栓风险的分层能力。结果显示静脉血栓栓塞总体6个月发生率为2.6%(95%CI:2.1-3.1),低、中、高危组分别为2.1%、2.6%、3.7%;Khorana评分≥2分者静脉血栓栓塞风险为4.1%(95%CI:3.1-5.4)。结论认为Khorana评分可对这类患者进行血栓风险分层,但静脉血栓栓塞风险低于随机血栓预防试验,对常规一级预防的绝对获益提出疑问。

要点

  • Khorana评分可对接受免疫检查点抑制剂治疗的癌症患者进行6个月血栓栓塞风险分层。
  • 静脉血栓栓塞6个月总体发生率为2.6%(95%CI:2.1-3.1),低危组2.1%、中危组2.6%、高危组3.7%。
  • 按指南符合一级预防条件(Khorana评分≥2分)者静脉血栓栓塞风险为4.1%(95%CI:3.1-5.4)。

核心结论

  • Khorana评分能够对接受免疫检查点抑制剂治疗的癌症患者进行6个月血栓栓塞事件风险分层。
  • 静脉血栓栓塞风险低于随机血栓预防试验,对无选择人群中常规一级血栓预防的绝对获益提出疑问。

研究设计与样本

  • 研究人群和Khorana评分通过丹麦行政健康登记数据定义。
  • 纳入3946例启动免疫检查点抑制剂治疗且无其他抗凝指征的癌症患者。
  • 主要结局为启动检查点抑制剂治疗后6个月静脉血栓栓塞风险;次要结局为动脉血栓形成和任何血栓栓塞事件。
  • 死亡被视为竞争风险事件。

主要发现

  • 静脉血栓栓塞6个月总体发生率为2.6%(95%CI:2.1-3.1)。
  • 低危(评分0)、中危(评分1-2)、高危(评分≥3)Khorana分组的静脉血栓栓塞风险分别为2.1%(95%CI:1.5-3.0)、2.6%(95%CI:2.0-3.4)、3.7%(95%CI:2.1-5.9)。
  • 按指南符合一级血栓预防条件(Khorana评分≥2分)的患者静脉血栓栓塞风险为4.1%(95%CI:3.1-5.4)。
  • 较高的Khorana风险类别也与较高的6个月动脉血栓形成和任何血栓栓塞事件风险相关。

局限性

  • 静脉血栓栓塞风险低于随机血栓预防试验,对无选择人群中常规一级血栓预防的绝对获益提出疑问。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thrombosis is common among patients with cancer. Primary thromboprophylaxis guided by the Khorana score is endorsed by guidelines but recommendations rely mainly on data from patients treated with chemotherapy. OBJECTIVES: To explore if the Khorana score could risk stratify patients with cancer treated with immune checkpoint inhibitors according to risk of venous and arterial thrombosis. PATIENTS/METHODS: The study population and Khorana score were defined using administrative Danish health registries. The primary outcome was 6-month risk of venous thromboembolism after initiation of checkpoint inhibitor treatment. Secondary outcomes were arterial thrombosis and any thromboembolic event. Death was considered a competing risk event. RESULTS: Among 3946 patients with cancer initiating checkpoint inhibitor treatment without other indications for anticoagulation, the overall 6-month incidence of venous thromboembolism was 2.6% (95% confidence interval [CI]: 2.1-3.1). Risks were 2.1% (95% CI: 1.5-3.0), 2.6% (95% CI: 2.0-3.4), and 3.7% (95% CI: 2.1-5.9) in low (score 0), intermediate (score 1-2), and high risk (score ≥3) Khorana categories, respectively. Among patients eligible for primary thromboprophylaxis according to guidelines (Khorana score ≥2), risk of venous thromboembolism was 4.1% (95% CI: 3.1-5.4). Higher Khorana risk category was also associated with higher 6-month risk of both arterial thrombosis and any thromboembolic events. CONCLUSIONS: The Khorana score was able to risk stratify patients with cancer treated with immune checkpoint inhibitors according to 6-month risk of thromboembolic events. Risks of venous thromboembolism were lower than in randomized thromboprophylaxis trials, thus questioning the absolute benefit of routine primary thromboprophylaxis in an unselected population of patients treated with immune checkpoint inhibitors.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Overvad TF, Skjøth F, Piazza G, et al. The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study. J Thromb Haemost. 2022. PMID: 36112135. doi:10.1111/jth.15883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。